HC Wainwright Reiterates Buy Rating for Neumora Therapeutics (NASDAQ:NMRA)

HC Wainwright reiterated their buy rating on shares of Neumora Therapeutics (NASDAQ:NMRA) in a report published on Monday morning,Benzinga reports. HC Wainwright currently has a $30.00 target price on the stock. HC Wainwright also issued estimates for Neumora Therapeutics’ Q1 2025 earnings at ($0.46) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.43) EPS and Q4 2025 earnings at ($0.44) EPS.

A number of other research firms have also commented on NMRA. Royal Bank of Canada reiterated an “outperform” rating and issued a $29.00 price target on shares of Neumora Therapeutics in a research report on Friday, November 22nd. JPMorgan Chase & Co. cut Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $23.40.

Neumora Therapeutics Price Performance

Shares of NASDAQ NMRA opened at $10.18 on Monday. Neumora Therapeutics has a 1 year low of $8.33 and a 1 year high of $21.00. The firm has a market cap of $1.64 billion, a PE ratio of -5.44 and a beta of 3.34. The company has a 50 day simple moving average of $11.80 and a 200 day simple moving average of $11.53.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same quarter in the previous year, the company earned ($1.14) EPS. As a group, research analysts anticipate that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Robert A. Lenz sold 5,563 shares of the firm’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the sale, the insider now owns 322,966 shares of the company’s stock, valued at $4,847,719.66. This trade represents a 1.69 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Matthew K. Fust sold 14,049 shares of the business’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the transaction, the director now owns 20,100 shares in the company, valued at $342,303. The trade was a 41.14 % decrease in their position. The disclosure for this sale can be found here. 26.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Neumora Therapeutics

A number of large investors have recently bought and sold shares of NMRA. Amalgamated Bank boosted its position in shares of Neumora Therapeutics by 472.8% during the 2nd quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after purchasing an additional 2,402 shares in the last quarter. Quarry LP acquired a new position in Neumora Therapeutics during the 2nd quarter worth approximately $98,000. Intech Investment Management LLC bought a new position in Neumora Therapeutics in the third quarter worth approximately $175,000. Ballentine Partners LLC acquired a new stake in Neumora Therapeutics in the third quarter valued at approximately $178,000. Finally, SkyOak Wealth LLC acquired a new stake in Neumora Therapeutics in the second quarter valued at approximately $147,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.